Accelerate PhenoTest® BC Kit CE-IVD

Easier for the lab.
Earlier for clinicians.

Fast MIC results. Direct from positive blood cultures. Now with optional ID, and affordably priced.

—imagine the potential for patients.

Get Fast Answers

 
Accelerate PhenoTest® BC Kit

Hear firsthand the difference
fast MICs are making

Independent studies show the BC kit provides identification and susceptibility results with MICs about 40 hours faster than current methods.*

*based on peer-reviewed publications comparing IVD-cleared methods through June 2019. Actual time to results may vary.

Pair rapid MICs with
your existing workflow

Now you can use your existing ID test to get fast AST results using the Accelerate PhenoTest BC kit.

It’s your lab after all, so do it your way.

AST: request item 10104018*
ID / AST: request item 10102018
Accelerate PhenoTest® BC kit
AST: request item 10104018
ID / AST: request item 10102018

Clinical relevancy

Timely escalation to effective therapy reduces mortality

Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5

4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45

Timely escalation to effective therapy reduces hospital length of stay

Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.

6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51

De-escalation can improve patient outcomes

% CDI Incidence by Number of Simultaneous Drug Classes Administered

Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7

Reporting antimicrobial susceptibility results approximately 40 hours faster than conventional methods gives clinicians the data required to optimize therapy 1-2 days faster.

7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416

Evidence matters.
See some results data. Hear about the impact.

Outcomes Data

Outcomes Data

Customer Stories

Customer Stories

Patient Cases

Patient Cases

Gram-Positive

ID: 6170
Field setting: eu
usa
Browser Locale: en_US
Raw locale: en_US
IP: 3.89.204.127
Identification
Ampicilin
Ceftaroline
Trimethoprim-
Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
Methicillin
resistance
(Cefoxitin)
S. aureus
S. lugdunensis
CoNS spp.
E. faecalis
E. faecium
Streptococcus spp.
S. agalactiae
S. aureus S. lugdunensis CoNS spp. E. faecalis E. faecium Streptococcus spp. S. agalactiae
Identification
Ampicilin
Ceftaroline
Trimethoprim-
Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
Methicillin resistance (Cefoxitin)

Gram-Negative

Identification
Ampicillin
Amox-Clav
Piperacillin-
Tazobactam
Ceftazidime-
Avibactam
Ceftolozane-
Tazobactam
Cefazolin
Cefuroxime
Ceftriaxone
Ceftazidime
Cefepime
Aztreonam
Ertapenem
Meropenem
Gentamicin
Tobramycin
Amikacin
Trimethoprim-
Sulfamethoxazole
Ciprofloxacin
Colistin
AmpC screen
(Cefoxitin)
E. coli
Klebsiella spp.
Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
E. coli Klebsiella spp. Enterobacter spp. Proteus spp. Citrobacter spp. S. marcescens P. aeruginosa A. baumannii
Identification
Ampicillin
Amox-Clav
Piperacillin-
Tazobactam
Ceftazidime-
Avibactam
Ceftolozane-
Tazobactam
Cefazolin
Cefuroxime
Ceftriaxone
Ceftazidime
Cefepime
Aztreonam
Ertapenem
Meropenem
Gentamicin
Tobramycin
Amikacin
Trimethoprim-
Sulfamethoxazole
Ciprofloxacin
Colistin
AmpC screen
(Cefoxitin)

Yeast

Identification
Candida albicans
Candida glabrata
 

Klebsiella spp.
K. oxytoca
K. pneumoniae

Enterobacter spp.
E. cloacae
E. aerogenes

Proteus spp.
P. mirabilis
P. vulgaris

Citrobacter spp.
C. freundii
C. koseri

CNS spp.
S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri

Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae

 
 

Specifications

Configurations:

AST: item 10104018*
ID/AST: item 10102018

Each configuration contains:

48-channel disposable test cassette
Reagent cartridge
Sample vial

The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.

1 Kit

Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm

Weight:
2.1 lb
950 g

Storage: 2.8°C

5 Pack, including packaging

Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm

Weight:
33 lb
15 kg

Publications

Oct 29, 2021

Real-World Impact of the Accelerate PhenoTest® BC Kit on patients with bloodstream infections in IOAS A Quasi-Experimental Multicenter Study
Clinical Infectious Diseases

Jul 13, 2021

Impact of the Accelerate PhenoTest® BC Kit on time to results for pathogens from bloodstream infections: IOAS (Improving Outcomes and Antibiotic Stewardship) study experience of 4 hospitals
ECCMID 2021

Jul 13, 2021

Evaluating the impact of the Accelerate PhenoTest® BC Kit on patients with bloodstream infections receiving ineffective empirical antibiotic treatment: IOAS study experience of 4 hospitals
ECCMID 2021

Jul 13, 2021

Antimicrobial use in patients with bloodstream infections from 4 hospitals in the Improving Outcomes and Antibiotic Stewardship (IOAS) study: a quasi-experimental multi-centre study of the Accelerate PhenoTest® BC Kit
ECCMID 2021

See all publications